PD1 signal transduction pathways in T cells

The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very...

Descripción completa

Detalles Bibliográficos
Autores principales: Arasanz, Hugo, Gato-Cañas, Maria, Zuazo, Miren, Ibañez-Vea, Maria, Breckpot, Karine, Kochan, Grazyna, Escors, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584302/
https://www.ncbi.nlm.nih.gov/pubmed/28881701
http://dx.doi.org/10.18632/oncotarget.17232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584302/
https://www.ncbi.nlm.nih.gov/pubmed/28881701
http://dx.doi.org/10.18632/oncotarget.17232

Ejemplares similares